vs
Cronos Group Inc.（CRON）与Regencell Bioscience Holdings Ltd（RGC）财务数据对比。点击上方公司名可切换其他公司
Cronos集团是全球性大麻素企业，主营大麻种植、加工及相关衍生产品的分销业务，产品线覆盖健康补充剂、快消品及医用大麻品类，主要服务北美、欧洲、亚太地区的合规娱乐与医用消费市场，严格遵循各地监管要求保障产品品质。
Regencell Bioscience Holdings Ltd是一家生物科技企业，专注于研发及商业化源自传统中药的治疗产品，核心管线覆盖神经退行性疾病、免疫类疾病等适应症，主要运营市场包括大中华区及其他亚洲区域。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
CRON
RGC
| Q4 25 | $44.5M | — | ||
| Q3 25 | $36.3M | — | ||
| Q2 25 | $33.5M | — | ||
| Q1 25 | $32.3M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $25.3M | — |
净利润CRONRGC
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $-39.7M | — | ||
| Q1 25 | $6.1M | — | ||
| Q4 24 | $43.7M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $-8.8M | — | ||
| Q1 24 | $-2.2M | — |
毛利率CRONRGC
| Q4 25 | 36.4% | — | ||
| Q3 25 | 50.4% | — | ||
| Q2 25 | 43.4% | — | ||
| Q1 25 | 42.6% | — | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 10.5% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 17.7% | — |
营业利润率CRONRGC
| Q4 25 | -16.8% | — | ||
| Q3 25 | -1.4% | — | ||
| Q2 25 | -15.9% | — | ||
| Q1 25 | -12.6% | — | ||
| Q4 24 | -37.5% | — | ||
| Q3 24 | -98.2% | — | ||
| Q2 24 | -56.1% | — | ||
| Q1 24 | -63.1% | — |
净利率CRONRGC
| Q4 25 | -4.1% | — | ||
| Q3 25 | 71.4% | — | ||
| Q2 25 | -118.7% | — | ||
| Q1 25 | 19.0% | — | ||
| Q4 24 | 144.3% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | -31.5% | — | ||
| Q1 24 | -8.9% | — |
每股收益（稀释后）CRONRGC
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $0.02 | — | ||
| Q4 24 | $0.12 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $-0.01 | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
